Analyst Reports

  • 23 Dec 2022

    Edison Investment Research Flash Note
    XanaMIA clears hurdle to start US recruitment

    Analysts: Pooya Hemami and Soo Romanoff

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 09 Dec 2022

    Edison Investment Research Flash Note
    XanaCIDD study in MDD underway

    Analysts: Pooya Hemami and Soo Romanoff

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 08 Dec 2022

    Edison Healthcare Insight: December 2022

    Analyst: Pooya Hemami
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 5 Dec 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 10 Nov 2022

    Edison Healthcare Insight: November 2022

    Analyst: Pooya Hemami
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 7 Nov 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 31 Oct 2022

    Edison themes: Neuroscience comeback
    Ripe for clinical innovation

    Analysts: Soo Romanoff and Dr Adam McCarter

    Refer to page 5 for Actinogen Medical 

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 19 Oct 2022

    Edison Investment Research Company outlook
    Actinogen – Cognitive enhancer targeting key diseases

    Analysts: Pooya Hemami and Soo Romanoff

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 12 May 2022

    Edison Healthcare Insight: May 2022

    Analyst: Soo Romanoff
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 9 May 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 14 Apr 2022

    Edison Healthcare Insight: April 2022

    Analyst: Jonas Peculias
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 11 April 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 17 Mar 2022

    Edison Healthcare Insight: March 2022

    Analyst: Jonas Peculias
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 14 March 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 10 Feb 2022

    Edison Healthcare Insight: February 2022

    Analyst: Jonas Peculias
    Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 7 February 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report

Latest results

2024 Half Year Financial Results

View Results Centre

2023 Annual General Meeting

Actinogen’s next Annual General Meeting

Date: November 2023 (TBA)

Read more

Back
to top